Skip to main content
Clinical Trials/EUCTR2017-001803-57-Outside-EU/EEA
EUCTR2017-001803-57-Outside-EU/EEA
Active, not recruiting
Phase 1

A randomized, study in healthy subjects to determine the bioavailability of 200 mg LCZ696 mini-tablet compared to the 200 mg LCZ696 final market image tablet

ovartis Pharmaceuticals Corp0 sites40 target enrollmentAugust 14, 2017

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Study in healthy subjects
Sponsor
ovartis Pharmaceuticals Corp
Enrollment
40
Status
Active, not recruiting
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 14, 2017
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
ovartis Pharmaceuticals Corp

Eligibility Criteria

Inclusion Criteria

  • Healthy male and female subjects of non\-child bearing potential, age 18 to 55 years of age included, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
  • Other protocol\-defined inclusion criteria may apply.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 40
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Use of investigational drugs within 30 days or 5 half\-lives of enrollment, whichever is longer. History of symptomatic orthostatic hypotension or syncope or clinically significant ECG abnormalities.
  • Other protocol\-defined exclusion criteria may apply.

Outcomes

Primary Outcomes

Not specified

Similar Trials